LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

Home・Aandelen Lijst・Avita Therapeutics Inc

Avita Therapeutics Inc

Open

3.5 3.24

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.35

Max

3.62

Belangrijke statistieken
By Trading Economics
Inkomsten	-3.3M -13M
Verkoop	-1.4M 17M
EPS	-0.712
Winstmarge	-77.289
Werknemers	260
EBITDA	-3.2M -11M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+23.55% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-16M 105M
Vorige openingsprijs	0.26
Vorige sluitingsprijs	3.5

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

8.83 / 9.77 Steun & Weerstand

Avita Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 dec 2025, 15:21 UTC

Winsten

Correction to Home Depot Outlook Headline on Dec. 9

23 dec 2025, 23:54 UTC

Marktinformatie

Gold Climbs Above $4,500/oz for First Time Amid Rising Geopolitical Tensions -- Market Talk

23 dec 2025, 23:40 UTC

Marktinformatie

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

23 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

23 dec 2025, 21:21 UTC

Acquisities, Fusies, Overnames

St Barbara to Use Deposit Toward A$370 Million Subscription to Buy 50% of Simberi Unit

23 dec 2025, 21:20 UTC

Acquisities, Fusies, Overnames

St Barbara to Hold Deposit in Escrow

23 dec 2025, 21:20 UTC

Acquisities, Fusies, Overnames

St Barbara: Deposit Represents Progress on Lingbao's Strategic Investment in Simberi Mine

23 dec 2025, 21:19 UTC

Acquisities, Fusies, Overnames

St Barbara Receives A$32 Million Deposit From Lingbao Gold

23 dec 2025, 21:13 UTC

Acquisities, Fusies, Overnames

ServiceNow Bets on Cybersecurity to Boost Growth -- Analysis

23 dec 2025, 20:16 UTC

Marktinformatie

Oil Futures Settle Higher on Geopolitical Tensions -- Market Talk

23 dec 2025, 20:14 UTC

Marktinformatie

U.S. Natural Gas Soars on Colder Weather Outlook -- Market Talk

23 dec 2025, 19:13 UTC

Winsten

Acquisities, Fusies, Overnames

Mergers and Acquisitions Soared This Year. 2026 Could Be Even Bigger. -- Barrons.com

23 dec 2025, 18:58 UTC

Marktinformatie

Gold Has Another Record-Setting Day -- Market Talk

23 dec 2025, 18:32 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 3 to 409 -- Market Talk

23 dec 2025, 17:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

23 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

23 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

23 dec 2025, 17:09 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Armis Seen as Good Fit for ServiceNow in $7.8B Deal -- Market Talk

23 dec 2025, 16:21 UTC

Marktinformatie

Monthly Canadian GDP Points to Flat Activity So Far for 4Q -- Market Talk

23 dec 2025, 16:16 UTC

Marktinformatie

Recent 'Disorderly' Yen Falls Could Justify Intervention -- Market Talk

23 dec 2025, 16:15 UTC

Marktinformatie

Precious Metals Pare Gains -- Market Talk

23 dec 2025, 16:03 UTC

Acquisities, Fusies, Overnames

Erste Group Bank: Closing Expected Around Mid-January

23 dec 2025, 16:03 UTC

Acquisities, Fusies, Overnames

Erste Group Bank Also Obtained Regulatory Approvals for 50% Stake in Santander Towarzystwo Funduszy Inwestycyjnych

23 dec 2025, 16:02 UTC

Acquisities, Fusies, Overnames

Erste Group Bank Obtained Regulatory Approvals by Polish Regulator KNF for Acquisition of Roughly 49% Controlling Stake in Santander Bank Polska

23 dec 2025, 16:01 UTC

Acquisities, Fusies, Overnames

Erste Group Bank Receives Green Light for Acquisition in Poland

23 dec 2025, 15:42 UTC

Acquisities, Fusies, Overnames

Telefonica: Agreement is For Sale of Telefonica Tech Business in Colombia, Mexico, Chile

23 dec 2025, 15:42 UTC

Acquisities, Fusies, Overnames

Telefonica Doesn't Set Out Financial Details of Divestment

23 dec 2025, 15:41 UTC

Acquisities, Fusies, Overnames

Telefonica: Deal Will Allow Focus on Core Markets

23 dec 2025, 15:40 UTC

Acquisities, Fusies, Overnames

Telefonica To Sell Telefonica Tech South American Business to Hiberus

23 dec 2025, 15:19 UTC

Marktinformatie

Fixed-Income Traders Misread Underlying Strength of Canada Economy -- Market Talk

Peer Vergelijking

Prijswijziging

Avita Therapeutics Inc Prognose

Koersdoel

By TipRanks

23.55% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.25 USD 23.55%

Hoogste 5.5 USD

Laagste 3 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Avita Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan Avita Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

8.83 / 9.77Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.